Clinical review of risperidone
Chouinard, G.; Arnott, W.
Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 38(Suppl 3): S89-S95
1993
ISSN/ISBN: 0706-7437 PMID: 7504574 Document Number: 5099
Phase II clinical trials with risperidone have proven it to have a potent antipsychotic effect, improving both positive and negative symptoms of schizophrenia. It was found to have a low potential for inducing extrapyramidal symptoms and has been shown to have a possible antidyskinetic effect without increasing parkinsonism. Risperidone has a rapid onset of action and a favourable side-effect profile. One-year data on risperidone suggest that its therapeutic action in patients with chronic schizophrenia can be maintained without the significant neurological side-effects associated with the use of standard neuroleptics.
Document emailed within 1 workday
